Insider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires 26,963 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe bought 26,963 shares of Inhibrx stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $15.05 per share, for a total transaction of $405,793.15. Following the completion of the acquisition, the chief executive officer now directly owns 692,511 shares in the company, valued at $10,422,290.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Lappe also recently made the following trade(s):

• On Monday, September 16th, Mark Lappe acquired 13,037 shares of Inhibrx stock. The stock was acquired at an average cost of $17.13 per share, for a total transaction of $223,323.81.
• On Monday, September 9th, Mark Lappe acquired 9,500 shares of Inhibrx stock. The shares were purchased at an average cost of $15.21 per share, for a total transaction of $144,495.00.
• On Friday, September 6th, Mark Lappe acquired 26,000 shares of Inhibrx stock. The stock was purchased at an average price of $15.29 per share, with a total value of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe purchased 20,000 shares of Inhibrx stock. The stock was bought at an average cost of $15.81 per share, for a total transaction of $316,200.00.
• On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were bought at an average price of $14.03 per share, for a total transaction of $140,300.00.

Inhibrx Trading Up 6.2 %

Shares of NASDAQ INBX traded up $1.02 during mid-day trading on Monday, reaching $17.43. 186,839 shares of the company’s stock were exchanged, compared to its average volume of 176,803. The business has a fifty day simple moving average of $13.63 and a 200 day simple moving average of $23.74. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $18.95.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share for the quarter, beating the consensus estimate of ($3.60) by $129.08. The company had revenue of $0.10 million during the quarter. Sell-side analysts anticipate that Inhibrx, Inc. will post 87.5 earnings per share for the current fiscal year.

Institutional Trading of Inhibrx

A number of institutional investors have recently modified their holdings of the company. Vestal Point Capital LP acquired a new position in Inhibrx during the 4th quarter worth approximately $58,140,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Inhibrx during the 4th quarter worth approximately $894,000. HCR Wealth Advisors acquired a new stake in shares of Inhibrx in the 4th quarter valued at approximately $239,000. Entropy Technologies LP bought a new position in shares of Inhibrx in the first quarter valued at $384,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Inhibrx by 7.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,920 shares of the company’s stock worth $766,000 after buying an additional 1,426 shares during the last quarter. 82.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, JMP Securities began coverage on shares of Inhibrx in a research note on Tuesday, July 23rd. They issued a “market perform” rating for the company.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.